CytomX Therapeutics, Inc.

NASDAQ:CTMX

Biotechnology

Healthcare
$1.88 -0.91%

-$0.03 today

Market cap
$409.85M
Beta
2.09
P/E (TTM)
-8.8
EPS (TTM)
-$0.33
52W Low $1.72High $8.21

Volume 4.39M

Average 4.99M

CTMX Income Before Tax

Profit after all operating and non-operating items but before income tax.

CytomX Therapeutics, Inc.NASDAQ: CTMX

Income Before Tax · Q1 FY2026 · quarter ended Mar 2026

Income before tax turns negative

Q1 FY2026 income before tax was -$18.19M, compared with $23.59M a year earlier. Trailing-twelve-month income before tax was -$58.91M.

Context

  • Income before tax amounted to 22.5% of revenue in FY2025, down 0.8 pp from a year earlier.
  • Income before tax increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly income before tax holds near -$18.19M or moves back toward the trailing-twelve-month quarterly average of -$14.73M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$18.19M+31.2% QoQ
Last fiscal yearDec 2025
-$17.13M-153.4% YoY
LTMMar 2026
-$58.91M-240.8% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-177.1%——
1 year-153.4%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(17.13M) USD
Year-over-year change
-153.4%

Income Before Tax vs competitors

How CTMX compares with its peers on the latest reported figures

  • CTMX's LTM Mar 2026 income before tax of -$58.91M is the 4th highest of the 10 companies compared; the peer median is -$80.35M.
  • Its year-over-year change of -240.8% is the lowest of 9, against a peer median of +13.9%.
  • Income before tax amounts to 165.7% of revenue for CTMX, versus a peer median of 154.3%.
CTMX Competitors Peer median
Income Before Tax for CTMX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NRIXNurix Therapeutics, Inc.LTM Aug 2026$308.21M +226.3%—43.9%
ZYMEZymeworks Inc.LTM Sep 2026$40.12M +171.6%—15.1%
ADAGAdagene Inc.LTM Jun 2024-$32.47M ——3980.4%
CTMXCytomX Therapeutics, Inc.LTM Mar 2026-$58.91M -240.8%—165.7%
MGNXMacroGenics, Inc.LTM Mar 2026-$71.03M -29.5%—45.2%
PYXSPyxis Oncology, Inc.LTM Mar 2026-$80.35M +17.5%—579.8%
ADCTADC Therapeutics S.A.LTM Mar 2026-$136.14M +9.0%—171.9%
STROSutro Biopharma, Inc.LTM Mar 2026-$153.72M +36.7%—154.3%
XNCRXencor, Inc.LTM Jun 2026-$160.85M +10.3%—153.2%
CLDXCelldex Therapeutics, Inc.LTM Sep 2026-$309.11M -37.7%—275986.6%
VRXAVeraxa Biotech Holding AG—— ———
Peer median (excluding CTMX) -$80.35M+13.9%—154.3%

Competitors are the stored peer set for CTMX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue37.31M53.16M101.21M138.1M76.2M
Cost of Revenue00000
Gross Profit37.31M53.16M101.21M138.1M76.2M
Gross Margin100.0%100.0%100.0%100.0%100.0%
Research & Development114.19M111.65M77.68M83.38M68.73M
Selling, General & Admin39.16M42.85M30.02M29.73M29.84M
Operating Expenses153.35M154.5M107.7M113.11M98.57M
Depreciation & Amortization2.71M2.44M2.18M1.77M1.38M
EBITDA(113.16M)(96.87M)5.5M33.86M(15.75M)
EBITDA Margin-303.3%-182.2%5.4%24.5%-20.7%
Operating Income(116.04M)(101.34M)(6.48M)25M(22.36M)
Operating Margin-311.0%-190.6%-6.4%18.1%-29.3%
Interest Income255K1.68M9.84M7.14M5.21M
Interest Expense00000
Other Income / Expenses172K2.02M9.81M7.1M5.23M
Income Before Tax(115.87M)(99.32M)3.32M32.09M(17.13M)
Pre-Tax Margin-310.5%-186.8%3.3%23.2%-22.5%
Income Tax Expense003.89M224K238K
Net Income(115.87M)(99.32M)(569K)31.87M(17.37M)
Net Margin-310.5%-186.8%-0.6%23.1%-22.8%
EPS (Basic)(1.26)(1.48)(0.01)0.38(0.15)
EPS (Diluted)(1.26)(1.48)(0.01)0.38(0.15)
Weighted Avg Shares64.15M65.74M73.81M84.44M137.94M
Weighted Avg Shares (Diluted)64.15M65.74M73.81M84.75M137.94M

CytomX Therapeutics, Inc.

NASDAQ:CTMX

Intrinsic Alpha fair value

Locked

Current Price

$1.88

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.